Latest On Crinetics Pharmaceuticals, Inc (CRNX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-25 19:43 EST | News | Crinetics Pharmaceuticals And Its Value Proposition In Acromegaly | N/A |  |
| 2023-05-04 23:54 EST | News | Crinetics Pharmaceuticals GAAP EPS of -$0.85 misses by $0.01, revenue of $2.67M beats by $2.43M | N/A | |
| 2023-03-06 12:48 EST | News | Evaluating Crinetics' Oral Long Shot For Acromegaly | N/A | |
| 2023-02-28 18:44 EST | News | Crinetics Pharmaceuticals GAAP EPS of -$0.84 misses by $0.01, revenue of $0.71M beats by $0.41M | N/A | |
| 2022-12-30 22:15 EST | News | Crinetics: FY23 Could Be Turning Point With Two Phase 3 Acromegaly Readouts | N/A | |
About Crinetics Pharmaceuticals, Inc (CRNX):
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors. The company is also developing CRN01941, an oral selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; an oral selective nonpeptide somatostatin type 5 receptor agonist for treating congenital hyperinsulinism; and an oral adrenocorticotrophic hormone antagonist for the treatment of cushing's and congenital adrenal hyperplasia diseas read more...es. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
General
- Name Crinetics Pharmaceuticals, Inc
- Symbol CRNX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 68
- Fiscal Year EndDecember
- IPO Date2018-07-18
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.crinetics.com
Valuation
- Price/Sales (Trailing 12 Mt.) 1102.47
- Price/Book (Most Recent Quarter) 2.99
- Enterprise Value Revenue 961.96
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.55
- Operating Margin -17443%
- Return on Assets -25%
- Return on Equity -42%
- Revenue 392000
- Earnings Per Share -$1.62
- Revenue Per Share $0.01
- Gross Profit -40313000
- Quarterly Earnings Growth -80.7%
Highlights
- Market Capitalization 531.37 million
- EBITDA -40113000
- PE Ratio -16.43
- Analyst Target Price $33.6
- Book Value Per Share $5.69
Share Statistics
- Shares Outstanding 32.92 million
- Shares Float 20.69 million
- % Held by Insiders 450%
- % Held by Institutions 95.14%
- Shares Short 1.53 million
- Shares Short Prior Month 1.38 million
- Short Ratio 13.29
- Short % of Float 6%
- Short % of Shares Outstanding 5%
Technicals
- Beta 1.23
- 52 Week High $23.7
- 52 Week Low $11.61
- 50 Day Moving Average 15.77
- 200 Day Moving Average 14.69
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Crinetics Pharmaceuticals, Inc (CRNX) Dividend Calendar:
Crinetics Pharmaceuticals, Inc (CRNX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Crinetics Pharmaceuticals, Inc (CRNX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Crinetics Pharmaceuticals, Inc (CRNX) Chart:
Crinetics Pharmaceuticals, Inc (CRNX) News:
Below you will find a list of latest news for Crinetics Pharmaceuticals, Inc (CRNX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Crinetics Pharmaceuticals, Inc (CRNX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest CRNX Trades:
Crinetics Pharmaceuticals, Inc (CRNX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | 8-K (Current report) | |
| 2020-11-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-10-26 | 8-K (Current report) | |
| 2020-09-21 | 8-K (Current report) | |
| 2020-09-03 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-09-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-03 | 8-K (Current report) | |
| 2020-08-07 | 8-K (Current report) | |
| 2020-08-07 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-22 | 8-K (Current report) | |
| 2020-06-11 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-05-08 | 8-K (Current report) | |
| 2020-05-08 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
Crinetics Pharmaceuticals, Inc (CRNX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Crinetics Pharmaceuticals, Inc (CRNX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 450%
Institutional Ownership: 9514%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-07-16 | Richard Scott Struthers | President & CEO | Sell | 17,500.00 | 14.46 | 253,107.75 | 890,805.00 | |
| 2020-07-15 | Richard Scott Struthers | President & CEO | Sell | 17,500.00 | 15.30 | 267,722.00 | 908,305.00 | |
| 2020-04-28 | WENDALL WIERENGA | Director | Buy | 25,329.00 | 0.73 | 18,490.17 | 99,846.00 | |
| 2020-04-17 | Vivo Capital VIII, LLC | 10% Share Holder | Sell | 74,333.00 | 15.40 | 1,144,728.20 | 2,162,587.00 | |
| 2020-04-17 | Vivo Capital VIII, LLC | 10% Share Holder | Sell | 10,265.00 | 15.40 | 158,081.00 | 298,625.00 | |
| 2020-04-17 | PERCEPTIVE ADVISORS LLC | 10% Share Holder | Buy | 1,071,428.00 | 14.00 | 14,999,992.00 | 3,659,381.00 | |
| 2020-04-16 | Vivo Capital VIII, LLC | 10% Share Holder | Sell | 26,527.00 | 15.20 | 403,210.40 | 2,236,920.00 | |
| 2020-04-16 | Vivo Capital VIII, LLC | 10% Share Holder | Sell | 3,663.00 | 15.20 | 55,677.60 | 308,890.00 | |
| 2020-04-15 | Vivo Capital VIII, LLC | 10% Share Holder | Sell | 189,625.00 | 15.50 | 2,939,187.50 | 2,263,447.00 | |
| 2020-04-15 | Vivo Capital VIII, LLC | 10% Share Holder | Sell | 26,185.00 | 15.50 | 405,867.50 | 312,553.00 | |
| 2020-04-07 | Vivo Capital VIII, LLC | 10% Share Holder | Sell | 5,373.00 | 14.20 | 76,296.60 | 2,453,072.00 | |
| 2020-04-07 | Vivo Capital VIII, LLC | 10% Share Holder | Sell | 742.00 | 14.20 | 10,536.40 | 338,738.00 | |
| 2020-04-03 | Vivo Capital VIII, LLC | 10% Share Holder | Sell | 263,600.00 | 13.80 | 3,637,680.00 | 2,458,445.00 | |
| 2020-04-03 | Vivo Capital VIII, LLC | 10% Share Holder | Sell | 36,400.00 | 13.80 | 502,320.00 | 339,480.00 | |
| 2020-03-09 | Vivo Capital VIII, LLC | 10% Share Holder | Sell | 133.00 | 19.50 | 2,593.50 | 168,165.00 | |
| 2020-03-09 | Vivo Capital VIII, LLC | 10% Share Holder | Sell | 347.00 | 19.50 | 6,766.50 | 2,722,045.00 | |
| 2020-03-09 | Vivo Capital VIII, LLC | 10% Share Holder | Sell | 48.00 | 19.50 | 936.00 | 375,880.00 | |
| 2020-02-10 | Vivo Capital VIII, LLC | 10% Share Holder | Sell | 5,904.00 | 21.40 | 126,345.60 | 168,298.00 | |
| 2020-02-10 | Vivo Capital VIII, LLC | 10% Share Holder | Sell | 1,451.00 | 21.40 | 31,051.40 | 2,722,392.00 | |
| 2020-02-10 | Vivo Capital VIII, LLC | 10% Share Holder | Sell | 200.00 | 21.40 | 4,280.00 | 375,928.00 | |